WHEN the Senate resumes today, January 15, its public inquiry into the government’s procurement of vaccines against Covid-19, it will be entirely fitting for our senators to ask 1) about the prices of the vaccines that have been ordered and 2) about the efficacy and safety of the vaccines.

It will also be appropriate for lawmakers to ask whether specific Covid-19 vaccines will be effective against the dreaded new variant of the disease, which is reported to be already in the country.